Targeted therapy in lymphoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Urgent need for novel lymphoma treatments with improved survival and reduced toxicity.
• Advances in understanding lymphoma molecular pathogenesis reveal key aberrant signal transduction pathways.

Purpose of the Study:

• To review the rationale and findings for targeted therapies in lymphoma treatment.
• To summarize investigations of mammalian target of rapamycin (mTOR) inhibitors and other small molecule agents.

Main Methods:

• Review of published data on targeted therapies for aggressive, relapsed/refractory lymphoma.
• Focus on drugs targeting the ubiquitin-proteasome and Akt/mammalian target of rapamycin (mTOR) pathways.

Main Results:

• Bortezomib (protease inhibitor) and mTOR inhibitors (temsirolimus, everolimus, ridaforolimus) are under investigation.
• Initial and ongoing studies are evaluating these targeted agents in lymphoma.

Conclusions:

• Targeted therapies offer a promising new avenue for lymphoma treatment.
• Further research into mTOR inhibitors and other small molecules is crucial for clinical application.